Buy or sell Cartiva stock pre IPO via an EquityZen fund
Cartiva is a developer of innovative products for the treatment of cartilage injuries and osteoarthritis.
About Cartiva Stock
Cartiva, Inc., located in Alpharetta, Georgia, is a private, venture capital-backed company that was spun out from Carticept Medical, Inc. in December 2011. Cartiva is dedicated to improving the quality of life for patients with osteoarthritis or cartilage damage through the development of novel therapies. An estimated 27 million Americans suffer from osteoarthritis, a chronic degenerative joint disease characterized by the breakdown of the cartilage in the joint. An additional two million Americans injure the cartilage in their knees each year. Many people do not respond well to current medical treatments or are not eligible for major surgery such as a total joint replacement. Cartiva’s mission is to develop and market products to help physicians treat osteoarthritis and cartilage injuries and the related pain more effectively. Our management team, board of directors and medical advisors are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization.
Director, Clinical Affairs
Katie E. Strother
VP, Regulatory, Quality & Clinical Affairs
Deborah J. Moore
President, CEO & Board of Directors
Timothy J. Patrick
VP, Finance & CFO
Peter J. Pizzo